⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PSNL News
Personalis, Inc. Common Stock
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
businesswire.com
PSNL
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
businesswire.com
PSNL
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
businesswire.com
PSNL
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
businesswire.com
PSNL
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
businesswire.com
PSNL
Smart Oncology: 5 Stocks Chasing the $317B Prize
prnewswire.com
ONCY
EXAS
VCYT
HOLX
PSNL
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
businesswire.com
PSNL
Personalis to Participate in the Piper Sandler 37 th Annual Healthcare Conference
businesswire.com
PSNL
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
businesswire.com
PSNL